an advisory panel of the us food and drug administration fda yesterday recommended marketing approval for the drug taxol to treat ovarian cancer which does not respond to standard treatment writes karen zagor in new york bristolmyers squibb the manufacturer said it submitted its new drug application about two and a half years ahead of schedule the fda usually follows the panels recommendations analysts have predicted sales of taxol derived from the bark of rare pacific yew trees of up to dollars 50m pounds 331m next year growing to about dollars 350m by 1995